R&D channel feed – Endpoints News

R&D channel feed

Centessa provides peek at rare disease drug from extremely tiny study, leaving several questions unanswered

4 years ago

Antisense technology changed one devastating disease. Why hasn't it transformed others?

4 years ago

Two decades after Gleevec approval, Novartis scores new CML OK for 'wild card' STAMP inhibitor

4 years ago

An Allergan psychiatric drug failed late-stage depression studies — but AbbVie is going for approval anyway

4 years ago

Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail

4 years ago

Scoop: Eli Lilly and AC Immune quietly scrapped Alzheimer’s studies for the centerpiece of $2B deal months ago

4 years ago

Ahead of closing $11.5B Acceleron buyout, Merck is on the hunt for more deals

4 years ago

Small biotech whiffs badly in PhIII pancreatic cancer study, prompting halt of another late-stage trial

4 years ago

Cheap SSRI drug proves successful in reducing Covid-related hospitalization times in large trial

4 years ago

Eli Lilly scraps a tau program for Alzheimer’s, echoing past failures and casting doubt on entire approach

4 years ago

Takeda swoops in and scoops up a cell therapy startup in buyout deal, expanding oncology pipeline

4 years ago

Angion's organ damage drug strikes out again, this time in high-risk kidney transplant patients

4 years ago

An Alzheimer's darkhorse fails its first big trial, but offers hope for a long-overlooked hypothesis

4 years ago

Novartis dumps AveXis program for Rett syndrome after failing repeat round of preclinical testing

4 years ago

Eli Lilly tosses a marquee pain drug and hits the gas on Alzheimer’s — as Biogen’s suffering opens market to rivals

4 years ago

FDA is much worse than its regulatory peers at proactively disclosing data, researchers find

4 years ago

Merck's experimental HIV drug islatravir hits with a PhIII combo win and FDA filing plans

4 years ago

A transatlantic biotech flags a painful PhIII cancer flop, waving a white flag

4 years ago

Another NASH player retreats from battered field after toxicology study flags potential delay

4 years ago

Sanofi, Regeneron gear up for new Dupixent filing after clearing second PhIII for eosinophilic esophagitis

4 years ago

Novartis' second attempt to replicate a stunning cancer result falls flat

4 years ago

Ocular Therapeutix hammered by a PhII failure in dry eye disease — shares tank

4 years ago

No, scientists are not any closer to pig-to-human transplants than they were last week

4 years ago

Sanofi, Regeneron etch out another PhIII victory for Dupixent, easing severe itch and clearing lesions

4 years ago

First page Previous page 155 156 157158159 160 161 Next page Last page